Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study by Harding, James J, MD, Fan, Jia, MD, Oh, Do-Youn, MD, Choi, Hye Jin, MD, Kim, Jin Won, MD, Chang, Heung-Moon, MD, Bao, Lequn, MD, Sun, Hui-Chuan, MD, Macarulla, Teresa, MD, Xie, Feng, MD, Metges, Jean-Phillippe, MD, Ying, Jie'er, MD, Bridgewater, John, MD, Lee, Myung-Ah, MD, Tejani, Mohamedtaki A, MD, Chen, Emerson Y, MD, Kim, Dong Uk, MD, Wasan, Harpreet, MD, Ducreux, Michel, MD, Bao, Yuanyuan, MS, Boyken, Lisa, PhD, Ma, Jiafang, MD, Garfin, Phillip, MD, Pant, Shubham, MD

Get full text